These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 35677056)

  • 21. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
    Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
    Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Having it both ways: how STAT3 deficiency blocks graft-versus-host disease while preserving graft-versus-leukemia activity.
    Brandstadter JD; Outen R; Maillard I
    J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation.
    Fuchs KJ; Falkenburg JHF; Griffioen M
    Best Pract Res Clin Haematol; 2024 Jun; 37(2):101555. PubMed ID: 39098803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of GVHD without losing GVL effect: windows of opportunity.
    Zhang P; Chen BJ; Chao NJ
    Immunol Res; 2011 Apr; 49(1-3):49-55. PubMed ID: 21136200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
    Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
    Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
    Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
    Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
    Sykes M; Harty MW; Szot GL; Pearson DA
    Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
    Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
    Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation.
    Maurer K; Soiffer RJ
    Expert Rev Hematol; 2023; 16(12):943-962. PubMed ID: 37906445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
    Tsirigotis P; Shimoni A; Nagler A
    Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
    Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK
    Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
    Pang Y; Holtzman NG
    Best Pract Res Clin Haematol; 2023 Jun; 36(2):101475. PubMed ID: 37353287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naive T Cells in Graft Versus Host Disease and Graft Versus Leukemia: Innocent or Guilty?
    Dekker L; Sanders E; Lindemans CA; de Koning C; Nierkens S
    Front Immunol; 2022; 13():893545. PubMed ID: 35795679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-
    Huang Y; Zou Y; Jiao Y; Shi P; Nie X; Huang W; Xiong C; Choi M; Huang C; Macintyre AN; Nichols A; Li F; Li CY; MacIver NJ; Cardona DM; Brennan TV; Li Z; Chao NJ; Rathmell JC; Chen BJ
    Front Immunol; 2022; 13():751296. PubMed ID: 35296079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.